Results 211 to 220 of about 43,190 (248)

Exploring Internal Medicine by a Comparative Schematic Analysis of the Long-Term Outcomes of Anticoagulation Therapy in Atrial Fibrillation. [PDF]

Cureus
Gul W, Qaiser S, Abbas SM, Singh D, Sta Ines MCA, Asad L, Aftab Z, Shah MH, Mzahri EUH.   +8 more
europepmc   +1 more source

Rivaroxaban in Clinical Practice for Atrial Fibrillation With Special Reference to Prothrombin Time

, 2014
Shinya Suzuki, Takayuki Otsuka, Koichi Sagara, Hiroto Kano, Shunsuke Matsuno, Yuko Kato, Hideaki Takai, Tokuhisa Uejima, Yuji Oikawa, Kazuyuki Nagashima, Hajime Kirigaya, Junji Yajima, Hitoshi Sawada, Tadanori Aizawa, Takeshi Yamashita   +14 more
openalex   +2 more sources

The efficacy of atorvastatin on inflammation and coagulation markers in high-risk thrombotic cancer patients undergoing chemotherapy: a randomized controlled trial. [PDF]

Thromb J
Setiawan B, Budianto W, Sukarnowati TW, Rizky D, Pangarsa EA, Santosa D, Sudoyo AW, Winarni TI, Riwanto I, Setiabudy RD, Suharti C.   +10 more
europepmc   +1 more source

Rivaroxaban in secondary prevention of cardioembolic stroke: standards and abnormal situations

, 2014
A. V. Fonyakin, Л.А. Гераскина   +1 more
openalex   +2 more sources

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

The Lancet Haematology, 2019
C. Male, A. Lensing, J. Palumbo, Riten Kumar, I. Nurmeev, Kerry M Hege, D. Bonnet, P. Connor, H. L. Hooimeijer, M. Torres, Anthony K. C. Chan, G. Kenet, S. Holzhauer, A. Santamaría, P. Amedro, E. Chalmers, P. Simioni, R. Bhat, D. Yee, O. Lvova, J. Beyer-Westendorf, T. Biss, I. Martinelli, P. Saracco, M. Peters, K. Kállay, Cynthia A. Gauger, M. Massicotte, G. Young, Á. Pap, Madhurima Majumder, William T. Smith, J. Heubach, S. Berkowitz, K. Thelen, D. Kubitza, M. Crowther, M. Prins, P. Monagle   +38 more
semanticscholar   +1 more source

Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs. [PDF]

J Vet Intern Med
Phillips EM, Blois SL, Abrams-Ogg ACG, Wood RD, Monteith G, Cuq B.   +5 more
europepmc   +1 more source

Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era. [PDF]

J Clin Med
Favaloro EJ, Pasalic L, Lippi G.
europepmc   +1 more source

Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study. [PDF]

BMC Cardiovasc Disord
Sridharan K, Sivaramakrishnan G.
europepmc   +1 more source

Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study. [PDF]

Eur Heart J Open
Luojus A, Lehto M, Halminen O, Lehtonen O, Niemi M, Teppo K, Kuoppala J, Haukka J, Putaala J, Linna M, Mustonen P, Aro A, Hartikainen J, Lip GYH, Airaksinen KEJ.   +14 more
europepmc   +1 more source